TradeWorks II

Tradeworks Group, Inc. is a Vermont-based nutraceutical and biotechnology company specialized in the development and commercialization of proprietary, science-backed health ingredients. The company is primarily known for its lead product, MaitakeGold 404, a multi-patented immune-support extract derived from the Maitake mushroom (Grifola frondosa). MaitakeGold 404 has been the subject of federally funded Phase I/II human clinical trials at Memorial Sloan-Kettering Cancer Center, specifically investigating its immunomodulatory effects in breast cancer patients. In 2017, the company was acquired by Innophos Holdings, Inc. as part of a larger acquisition that included its affiliates NutraGenesis and Icon Group. Today, it operates as part of a broader specialty ingredients portfolio focusing on immune health and wellness.